Objective:To investigate the clinical efficacy of compound glycyrrhizin combined with entecavir in the treatment of patients with early cirrhosis of chronic hepatitis B(referred to as early stage cirrhosis) and its mech anism. Methods:A total of 74 patients with early cirrhosis were randomly divided into the control group(n=36) and the experimental group(n=38). The control group was treated with entecavir, and the experimental group was treated with compound glycyrrhizin tablets every day on the basis of the control group. The course of treatment was 48 weeks. Liver function indicators such as alanine aminotransferase(ALT), aspartate aminotransferase(AST), albumin(ALB), prealbumin(PA), total bilirubin(TBIL), γ-glutamyl transpeptidase(γ-GT) content and HBV negative rate were measured before and after treatment in two groups. Fibroscan was used to measure the changes of liver elasticity. The levels of serum type Ⅲ procollagen(PⅢP), type Ⅳ collagen hyaluronic acid (HA) and laminin (LN) were measured by radioimmunoassay before and after treatment; And serum golgi protein 73(GP73) and fibronectin (Fn) were measured by ELISA. Results:The HBV negative rate and total effective rate in the experimental group were higher than those in the control group (P<0.05). Liver elasticity of the control group and the experimentaly group was significantly improved after treatment (P<0.05), while serum ALT, AST, γ-GT, TBIL, P Ⅲ P, HA, LN, Fn and GP73 contents was decreased, and the content of serum ALB and PA was increased (P<0.05). Compared with the control group, liver elasticity improvement trend was more obvious in the experimental group (P<0.05). The levels of serum ALT, AST, γ-GT, TBIL, PⅢP, HA, LN, Fn and GP73 in the experimental group were lower than those in the control group, and the content of ALB and PA was higher (P<0.05). Conclusion:Compound Glycyrrhizin Combined with entecavir is effective in the treatment of early cirrhosis, and its mechanism is related to anti-virus and improvement of liver fibrosis.
 王贵强,侯金林,魏来.慢性乙型肝炎防治指南(2015)[J].临床肝胆病杂志,2015, 23(12):888-905.
 PAPASTERGIOU V,LOMBARDI R,MACDONALD D,et al.Global epidemiology of hepatiti B virus(HBV) infection[J].Curr Hep Rep,2015,14(3):171-178.
 CINAFL J,MORGENSTERN B,BAUER G,et al.Glycyrrhizin:an active component of liquorice roots and replication of SARS-associated coronavirus[J].The Lancet,2003, 36(1):2045-2046.
 SU T H,KAO J H.Improving clinical outcomes of chronic hepatitis B virus infection[J].Expert Rev Gastroenterol Hepatol,2015,9(2):141-154.